Introduction: Who Should Get Tested for KRAS Mutations

If you have been diagnosed with certain types of cancer, testing for changes in the KRAS gene is an important part of understanding your condition. This is particularly true if you have been told you have cancer in your lungs, colon or rectum, or pancreas, as these are the cancers where KRAS mutations appear most frequently.^[1][4]

The KRAS gene provides instructions for making a protein that normally helps control how cells grow and divide. When this gene becomes mutated, the protein acts like a switch that gets stuck in the “on” position, causing cells to grow uncontrollably and form tumors.^[6] Understanding whether your cancer has this mutation is not just about knowing what went wrong—it directly affects which treatments will work best for you and which ones will not help at all.^[5]

All patients who have been diagnosed with stage 4 or metastatic (cancer that has spread to other parts of the body) colorectal cancer should have KRAS testing done.^[5] For lung cancer patients, particularly those with non-small cell lung cancer (the most common type of lung cancer), KRAS testing is also strongly recommended. The KRAS biomarker appears in approximately 15 to 25 percent of patients with non-small cell lung cancer.^[3][8]

Patients with pancreatic cancer should also discuss KRAS testing with their healthcare team. More than 90 percent of tumors in the most common type of pancreatic cancer—pancreatic ductal adenocarcinoma—are thought to have a KRAS mutation.^[16][25] This makes KRAS one of the most important genetic changes to look for when planning treatment for pancreatic disease.

The right time to seek KRAS testing is as soon as possible after receiving your cancer diagnosis, and ideally before starting any treatment. You should have the testing done and receive the results before beginning treatments such as chemotherapy or immunotherapy.^[8][14] Having this information up front allows your medical team to design a treatment plan that is tailored to your specific cancer biology from the very beginning.

Many cancer patients with KRAS mutations do not have any unusual signs or symptoms in the early stages of their disease, which is one reason why cancers carrying this mutation are often diagnosed at more advanced stages.^[8][14] This makes it even more important to pursue comprehensive testing once cancer has been found, rather than waiting for symptoms to worsen.

Classic Diagnostic Methods to Identify KRAS Mutations

Testing for KRAS mutations involves examining your tumor tissue or, in some cases, your blood to look for specific changes in the DNA of cancer cells. This testing is often referred to as biomarker testing, molecular profiling, tumor testing, or genomic testing.^[5][16] All these terms describe the same general process: analyzing the genetic makeup of your cancer to find important clues about how it behaves and responds to treatment.

Tissue Biopsy Testing

The most common and recommended way to test for KRAS mutations is through a tumor tissue sample, known as a biopsy. This sample can come from either the original tumor in your colon, lung, pancreas, or other organ, or from a tumor that has spread to another part of your body.^[5] In most cases, doctors can use tissue that was already collected during the initial biopsy performed to diagnose your cancer, so you may not need to undergo another procedure.^[8][14]

When a biopsy is performed specifically for KRAS testing, a small piece of tumor tissue is removed and sent to a specialized laboratory. Laboratory technicians then analyze the DNA within the cancer cells to see if there are mutations in the KRAS gene.^[16] The process typically looks for mutations at specific locations in the gene, most commonly at positions called codons 12, 13, and 61, where the vast majority of KRAS mutations occur.^[1][17]

Liquid Biopsy Testing

A newer approach to KRAS testing is called a liquid biopsy. This method analyzes fragments of tumor DNA that are floating in your bloodstream, known as circulating tumor DNA or ctDNA.^[5] A simple blood draw is all that is needed for this test, making it less invasive than a traditional tissue biopsy.

Liquid biopsies can be particularly helpful when it is difficult or risky to obtain a tissue sample, or when doctors want to monitor how your cancer is responding to treatment over time. However, tissue biopsy remains the gold standard and is the method most commonly recommended for initial KRAS mutation testing.

Testing Methods: Individual Testing and Multi-Gene Panels

KRAS can be tested individually, meaning the laboratory specifically looks only for changes in the KRAS gene. However, doctors often order what is called a multi-gene panel or comprehensive biomarker testing.^[5] This approach uses advanced technology called next-generation sequencing (NGS) to examine many different genes at once, including KRAS and other genes that might be mutated in your cancer.^[5]

Comprehensive testing is beneficial because it gives a complete picture of your tumor’s biology. Even if KRAS is the main focus, finding out about other genetic changes can reveal additional treatment options or clinical trials you might be eligible for.

Understanding Your Test Results

When your KRAS test results come back, they will typically be reported in one of two ways. If no KRAS mutation is found in your cancer, the result will be reported as “KRAS wild-type” or “KRAS WT.” The term “wild-type” simply means normal or non-mutated.^[5]

If a KRAS mutation is present, the report will say “KRAS mutant” and will usually specify exactly which mutation was found. For example, you might see “KRAS G12C” or “KRAS G12V” in your results.^[5] The letters and numbers refer to the specific location and type of change in the KRAS protein. This level of detail matters because different KRAS mutations can respond differently to treatments, and some newer drugs are designed to target only specific KRAS mutations.

Nearly all KRAS mutations found in lung cancer change one of two amino acids (the building blocks of proteins) in the K-Ras protein: either the amino acid glycine at position 12 or 13, or the amino acid glutamine at position 61.^[1] Colorectal cancers show similar patterns, with about 40 percent of these cancers having a KRAS mutation.^[5]

Where Testing Is Performed

KRAS testing can be performed at various types of facilities. NCI-Designated Comprehensive Cancer Centers (cancer centers designated by the National Cancer Institute) and other academic medical centers are excellent choices, as they have significant experience with comprehensive biomarker testing.^[8][14] Your doctor may also send your sample to a commercial laboratory that specializes in cancer genetics testing.

Some cancer centers and organizations offer programs to help patients access testing. For example, patients who cannot access testing in their local area may be eligible for free biomarker testing through specialized programs designed to ensure all patients receive the information they need.^[16][25]

Diagnostic Testing for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new combinations of existing treatments. For patients with KRAS-mutated cancers, clinical trials can provide access to cutting-edge therapies that are not yet available to the general public. However, getting into a clinical trial requires meeting specific criteria, and KRAS testing is often a key part of that qualification process.

Why KRAS Status Matters for Clinical Trials

Many clinical trials are designed specifically for patients whose cancers have particular genetic features. A trial might be testing a drug that only works on cancers with a KRAS mutation, or it might be looking at treatments for patients whose cancers do not have KRAS mutations. Knowing your KRAS status is therefore essential for determining which trials you are eligible to join.^[4]

Researchers designing clinical trials use KRAS testing results as both an inclusion criterion (something you must have to participate) and an exclusion criterion (something that would prevent you from participating). For example, a study of a new KRAS G12C inhibitor would only accept patients whose tumors have that specific G12C mutation. On the other hand, a trial testing a treatment that works better in KRAS wild-type cancers might exclude anyone with a KRAS mutation.

Standard Testing Requirements for Trial Entry

When enrolling in a clinical trial, you will typically need to provide documentation of your KRAS mutation status. This usually comes from the biomarker testing report generated by the laboratory that analyzed your tumor tissue or blood sample. The trial protocol—the detailed plan for how the study will be conducted—will specify exactly what information is needed.

For trials testing KRAS-targeted therapies, researchers often require confirmation not just that you have a KRAS mutation, but specifically which mutation subtype you have. The distinction between KRAS G12C, G12V, G12D, and other variants is critical because different drugs target different mutations.^[4][17] A drug designed for KRAS G12C will not work on KRAS G12V or other subtypes.

Sometimes, if your original KRAS testing was done several years ago or using older technology, clinical trial investigators may ask you to undergo repeat testing using more modern methods like next-generation sequencing. This ensures they have the most accurate and detailed information about your cancer’s genetic profile.

Additional Testing for Trial Eligibility

Beyond KRAS testing, clinical trials often require additional biomarker assessments to determine if you are a good candidate. These might include:

• Testing for other gene mutations that could affect how the experimental treatment works
• Measuring levels of specific proteins in your tumor tissue
• Assessing your tumor’s PD-L1 expression (a marker related to immune system activity)
• Evaluating the overall genetic stability of your cancer cells

All of these tests help researchers understand whether the experimental therapy is likely to work in your particular case and whether it is safe for you to receive it. The trial team will coordinate these tests, often using the same tumor sample that was used for your KRAS testing.

Monitoring During Clinical Trials

If you enroll in a clinical trial for a KRAS-targeted therapy, you will likely need periodic testing throughout the study. This might include repeat liquid biopsies to monitor your circulating tumor DNA levels, which can show whether the treatment is working to reduce the amount of cancer in your body. These tests also help researchers understand if your cancer is developing resistance to the experimental drug.^[10]

Researchers are particularly interested in understanding how cancer cells adapt to KRAS-targeted treatments. Sometimes tumors develop new mutations that allow them to bypass the drug’s effects, and monitoring tests can detect these changes.^[4][13] This information is valuable not only for managing your treatment but also for advancing scientific knowledge about how to overcome drug resistance.

Access to Experimental KRAS Inhibitors

Clinical trials have become an especially important pathway for patients with KRAS mutations because targeted therapies for these mutations are relatively new. While drugs targeting KRAS G12C have recently been approved by the Food and Drug Administration, inhibitors for other KRAS mutations are still primarily available only through clinical trials.^[4][12][13]

If your cancer has a KRAS mutation other than G12C—such as G12D, G12V, or G13D—participating in a clinical trial may be your best opportunity to receive a therapy specifically designed for your mutation subtype. Many research institutions are actively testing these next-generation KRAS inhibitors, and enrollment is ongoing.

Your healthcare team can help you search for clinical trials that match your KRAS mutation status. Several online databases maintained by the National Cancer Institute and other organizations allow you to search for trials based on your cancer type and genetic profile.